explore -WSS

explore

author：hotspot 2025-10-01 10:58:16 - browse：12583

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： MultiPlan and major insurers sued for alleged medical price

focus

WSS

FDA panel to weigh approval of NurOwn, controversial ALS drug

Second xenotransplant done with gene

Medical student insurance fails on mental health care coverage

Lasker Awards 2023: Winners in biomedical research

Ukraine and a new approach to mental health in war

Melinda French Gates resigns from Gates Foundation

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

Experts study whether long Covid risk adds up with each reinfection

Activists slam private health insurers over coverage restrictions

Drug for rare kidney disease narrowly misses mark in clinical trial

Psychedelics group wrestles with new pharma identity

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

It's been 20 years since Dolly the sheep. Where's my clone?

ChatGPT in medicine: STAT answers readers' burning questions

How AI helped researchers track recovery from depression

hotspot

Medical student insurance fails on mental health care coverage

How Vertex's cystic fibrosis drug is changing patients' lives

Close Medicare's dangerous gaps in addiction treatment coverage

H5N1 bird flu found in pasteurized milk: what we know

Why are Kaiser Permanente staff considering a strike?

After traumatic brain injury, life support decisions can use more time

explore

focus

entertainment

leisure time